No Data
No Data
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) Is a Great Choice
Context Therapeutics Price Target Announced at $4.50/Share by Piper Sandler
Context Therapeutics Price Target Announced at $4.50/Share by Piper Sandler
Express News | Piper Sandler Initiates Coverage On Context Therapeutics With Overweight Rating, Announces Price Target of $4.5
Optimistic Outlook for Context Therapeutics' CTIM-76 Based on Targeting Efficacy and Market Potential
Express News | Context Therapeutics 13G Filing Shows Avidity Partners Management LP Reported A 9.9% Stake In The Co As Of May 2, 2024
Express News | Avidity Partners Management LP Reports 9.9% Passive Stake in Context Therapeutics as of May 2- SEC Filing
No Data